Intramyocardial Gene Therapy Directed to Hibernating Heart Muscle Using a Combination of Electromechanical Mapping and Positron Emission Tomography

Human Gene Therapy

Volumn 27, Issue 10, 2016, Pages 830-834

  Hassinen, Iiro ^a   Kivelä, Antti ^a   Hedman, Antti ^a   Saraste, Antti ^b   Knuuti, Juhani ^b   Hartikainen, Juha ^a,c   Ylä Herttuala, Seppo ^a,c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIAC MAPPING SYSTEM; CARDIAC MUSCLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRIC ACTIVITY; ELECTROMECHANICAL MAPPING; GENE THERAPY; GENE TRANSFER; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HUMAN; MYOCARDIAL HIBERNATION; MYOCARDIAL PERFUSION IMAGING; POSITRON EMISSION TOMOGRAPHY; ADENOVIRIDAE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; ELECTROMYOGRAPHY; FEMALE; GENE VECTOR; GENETICS; HEART; HIBERNATION; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; THERAPEUTIC USE; UNSTABLE ANGINA PECTORIS; VERY ELDERLY;

ADENOVIRIDAE; ADULT; AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; CORONARY ARTERY DISEASE; ELECTROMYOGRAPHY; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEART; HIBERNATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY;

EID: 84989261706     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.131     Document Type: Article

References (15)

1. Williams B, MenonM, Satran D, et al. Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv 2010, 75:886-891.
2. Rutanen J, Rissanen TT, Markkanen JE, et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004;109: 1029-1035.
3. Byzova TV, Goldman CK, Jankau J, et al. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood 2002;99:4434-4442.
4. Rissanen TT, Markkanen JE, Gruchala M, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003, 92:1098-1106.
5. Kastrup J, Jørgensen E, Rück A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: The Euroinject One trial. J Am Coll Cardiol 2005;45:982-988.
6. Stewart DJ, Kutryk MJ, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009;17:1109-1115.
7. Berman DS, Kang X, Slomka PJ, et al. Underestimation of extent of ischemia by gated SPECT myocardial perfusion imaging in patients with left main coronary artery disease. J Nucl Cardiol 2007;14:521-528.
8. Danad I, Uusitalo V, Kero T, et al. Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease: cutoff values and diagnostic accuracy of quantitative 15O H2O PET imaging. J Am Coll Cardiol 2014;64:1464-1475.
9. Pavo N, Jakab A, Emmert MY, et al. Comparison of NOGA endocardial mapping and cardiac magnetic resonance imaging for determining infarct size and infarct transmurality for intramyocardial injection therapy using experimental data. PLoS One 2014;9:e113245.
10. Kuopio University Hospital. Endocardial Vascular Endothelial Growth Factor D (VEGF-D) Gene Therapy for the Treatment of Severe Coronary Heart Disease (KAT301). In Clinicaltrials. gov. Available from https://clinicaltrials. gov/ct2/show/NCT01002430 (accessed on September 10, 2016).
11. Saraste A, Ukkonen H, Varis A, et al. Effect of spinal cord stimulation on myocardial perfusion reserve in patients with refractory angina pectoris. Eur Heart J Cardiovasc Imaging 2015;16:449-455.
12. Westphal M, Ylä-Herttuala S, Martin J, et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:823-833.
13. Jauhiainen S, Häkkinen SK, Toivanen PI, et al. Vascular endothelial growth factor (VEGF)-D stimulates VEGF-A, stanniocalcin-1, and neuropilin-2 and has potent angiogenic effects. Arterioscler Thromb Vasc Biol 2011;31:1617-1624.
14. Nieminen T, Toivanen PI, Rintanen N, et al. The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features. Biochim Biophys Acta 2014;1840:454-463.
15. European Commission. Detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use; April 2006. Enterprise and industry directorate-general (Consumer goods, Pharmaceuticals); Brussels, ENTR/CT3, Revision 2.